|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the Center for Functional Genomics and Human
Disease, Monash Institute of Reproduction and Development, Monash
University, Clayton, Victoria, Australia.
The ability to modify responses to type I interferons (IFNs) could
alter processes such as hematopoiesis and immunity, which involve
endogenous IFNs and responses to exogenous IFNs. The data presented
here support a significant role for a recently identified soluble
isoform of the murine type I IFN receptor, muIfnar-2a, as an efficient
regulator of IFN responses. The messenger RNA (mRNA) transcript
encoding muIfnar-2a is generally more abundant than that encoding the
transmembrane isoform, muIfnar-2c. Furthermore, the ratio of
muIfnar-2a:2c transcripts varied from more than 10:1 in the
liver and other organs to less than 1:1 in bone-marrow macrophages,
indicating independent regulation of the 2 transcripts encoding
receptor isoforms and suggesting that the soluble muIfnar-2a levels are
biologically relevant in some organs. Western blot analysis showed that
soluble muIfnar-2 was present at high levels in murine serum and other
biologic fluids and bound type I IFN. Recombinant muIfnar-2a
competitively inhibited the activity of both IFN The type I interferons (IFNs) are a family of
cytokines produced in physiologic and pathologic conditions. Their
biologic activities include inhibition of macrophage and lymphocyte
proliferation, differentiation of macrophages, activation of natural
killer and dendritic cells, and increased survival of memory T cells in
addition to their well-characterized antiviral and antitumor
activities.1-6 These activities make type I IFNs important
mediators of physiologic processes and disease pathogenesis and useful
in the treatment of viral infections, some cancers (particularly those
of hematopoietic origin), and other diseases, including multiple
sclerosis.7
In both human and mouse, the type I IFNs include multiple IFN The role of IFNAR-1 and IFNAR-2 in binding type I IFNs has not been
fully defined. However, studies of cloned huIFNAR-1 and of mice with a
null mutation in the Ifnar-1 gene15,16
indicated that this component was essential for mediating antiviral
responses to type I IFNs. In addition, studies using bone
marrow-derived macrophages from muIfnar-1 To obtain data on the expression of muIfnar-2a and its biologic
activity, we have used the mouse model because the murine type I IFN
system is similar to the human system, and the mouse can be genetically
manipulated and is more amenable to study. We present the first direct
evidence for an important function for the receptor isoform muIfnar-2a.
The messenger RNA (mRNA) expression of muIfnar-2a varied in
different tissues and was generally more abundant. Soluble muIfnar-2
was detected at high levels in murine serum and other biologic fluids
and was able to bind type I IFN. We demonstrate, for the first time,
that recombinant muIfnar-2a can inhibit IFN Cell culture, interferons, and mice
Mice were maintained under standard conditions
Isolation and Northern analysis of poly(A)+ messenger RNA Poly(A)+ mRNA from normal mouse tissues, cell lines, and primary cells was prepared essentially as described.19 Northern blots of poly(A)+ mRNA were prepared and hybridized as previously described14 with a 32P-labeled muIfnar-2 cDNA14 and then washed using high-stringency conditions (0.2 X SSC, 0.1% SDS at 65°C). The blots were also probed with a 32P-labeled 1.2 kb PstI fragment of glyceraldehyde-3-phosphate (GAPDH) cDNA to normalize the different samples for RNA loading. To enable valid comparisons across separate filters, sets of RNA samples for quantification experiments were simultaneously electrophoresed, transferred to membranes, and probed with the same preparation of 32P-labeled probe. Northern blots were exposed to a phosphor screen, and a quantitative analysis was performed using a Fuji BAS 1000 PhosphorImage analyzer and MacBAS v2.5 software (Fuji, Melbourne, Australia).Construction of plasmids To generate recombinant muIfnar-2a protein using the bacterial expression vector pGEX-2T, a cDNA clone encoding muIfnar-2a14 was modified using Pfu polymerase (Stratagene, La Jolla, CA). A BamHI site was inserted at the 5' end immediately after the predicted leader peptide and an EcoRI site after the predicted stop codon to enable cloning, resulting in the construct pGEXmuIfnar-2a.To produce a recombinant extracellular domain (ECD) of muIfnar-2c, the
5' end of a cDNA clone encoding muIfnar-2c14 was modified
to encode a SnaBI site and an in-frame human
c-myc 9E10 epitope (SMEQKLISEEDLN).20 The yeast
The nucleotide sequences of all PCR-generated constructs were confirmed by dideoxy sequencing using an ABI PRISM Ready Reaction sequencing kit (PE Applied Biosystems, Scoresby, Australia). To generate plasmids encoding muIfnar-2 for expression in COS7 cells, a 3-kb EcoRV fragment containing the entire coding region of muIfnar-2c14 was ligated into the blunt-ended XbaI site of pEF-BOS.22 A HincII-SmaI fragment containing the entire coding region of muIfnar-2a14 was subcloned into the BstXI site of pEF-BOS after the addition of BstXI linkers. To construct a type I IFN-responsive reporter plasmid, a XbaI-SpeI fragment containing the 2'-5' oligoadenylate synthetase gene promoter was inserted into the NheI site of pGL3-Basic (Promega, Madison, WI). For stable cell line generation, a XhoI-SalI fragment containing the neomycin resistance gene from pMCINeo was inserted, resulting in the construct p2'5'OASLucNeo. Expression and purification of recombinant muIfnar-2c extracellular domain in Pichia pastoris To express recombinant muIfnar-2c ECD in P pastoris, the plasmid pmyc-Ifnar-2-His ECD was digested with either BglII or SalI to obtain recombinant clones with different methanol utilization phenotypes (His+Muts: methanol utilization slow, or His+Mut+: wild-type methanol utilization, respectively). Integration into host cells was accomplished by electroporation of his4 (GS115) P pastoris cells according to the manufacturer's recommendations (Invitrogen). Selection of yeast colonies expressing myc-muIfnar-2-His ECD (muIfnar-2 ECD, San Diego, CA) was carried out essentially as previously described23 using a 9E10 anti-myc antibody. The majority of the His+ transformants were 9E10 positive and were of the Mut+ phenotype. However, levels of protein expression appeared highest in the few 9E10+Muts positive clones, and hence, the highest-producing Muts clone was chosen for further experiments. This clone was cultured as previously described,23 except 1.5% methanol was added to induce the cells to express the heterologous protein. Expression of muIfnar-2 ECD was analyzed by SDS-PAGE of the culture supernatant, followed by Western blotting and detection with 9E10 antibody.P pastoris expression supernatant containing recombinant muIfnar-2 ECD protein was dialyzed in 20 mM Tris and 100 mM NaCl (pH 8.0) for 24 hours at 4°C. Adsorption of muIfnar-2 ECD protein to TALON cobalt resin (Clontech, Palo Alto, CA) was performed under native conditions according to the manufacturer's recommendations. The purified protein was concentrated using Centricon-10 columns (Amicon, North Ryde, Australia) according to the manufacturer's recommendations, and the purity assessed by SDS-PAGE, followed by silver staining.24 The protein concentration in the preparation was determined against bovine serum albumin (BSA) standards using Bradford25 reagent (Biorad, Richmond, VA). Approximately 328 µg was purified from a 600-mL culture (0.55 mg/L). Expression and purification of recombinant muIfnar-2a in Escherichia coli Recombinant muIfnar-2a was expressed as a fusion protein with glutathione S-transferase (GST) using Escherichia coli DH10B cells transformed with the plasmid pGEXmuIfnar-2a essentially as described previously.26 Benzamidine sepharose 50% (wt/vol) (Pharmacia, Piscataway, NJ) was added to the thrombin (Sigma, St Louis, MO)-cleaved protein preparation and incubated for 2 hours at 4°C to remove the residual thrombin. The purity and concentration of the protein preparation was determined as previously described, with approximately 80 to 100 µg/mL of recombinant muIfnar-2a protein obtained per preparation. SDS-PAGE analysis demonstrated a band of approximately 29 kd (data not shown) that was consistent with the predicted size of 28.9 kd derived from the cDNA sequence.14Antibody production For the first immunization, an equal volume of Freund's complete adjuvant was added to approximately 150 µg of purified muIfnar-2 ECD produced in P pastoris, and the emulsified mixture injected subcutaneously into multiple sites on New Zealand White rabbits. For subsequent immunizations, incomplete Freund's adjuvant was added to the same amount of purified protein. After 3 immunizations, the rabbits were bled and their sera collected. An antibody titer of 10 000 was confirmed by enzyme-linked immunosorbent assay (ELISA) using recombinant muIfnar-2 ECD and muIfnar-2a proteins as antigens, the collected sera as the primary antibody, horseradish peroxidase-conjugated goat antirabbit Ig as the secondary antibody (Silenus, Melbourne, Australia), and ABTS (Sigma) as a colorimetric substrate.Western blot analysis Proteins separated by SDS-PAGE were transferred onto prewetted Hybond-C Extra membranes using a transfer buffer containing 25 mM Tris, 192 mM Glycine, 0.1% SDS, 20% (vol/vol) methanol in a Semiphor transfer system (Hoeffer, Piscataway, NJ) at 100 mA for 1 to 2 hours. After transfer, membranes were incubated in 1% BSA (Sigma)/0.1% Tween-20 (ICN, Costa Mesa, CA) in phosphate-buffered saline (PBS) containing no sodium azide, followed by incubation with anti-muIfnar-2 ECD antibody and then with horseradish peroxidase-conjugated goat antirabbit Ig antibody (Silenus). Recombinant proteins were visualized with enhanced chemiluminescence (ECL) reagents (Supersignal; Pierce, Birminghamshire, United Kingdom), followed by autoradiography. In competition experiments, the primary antibody and competitor protein were preincubated together for 1 hour at 37°C before being added to the membrane. To deglycosylate proteins with endoglycosidase F (400 mU/mL) or O-glycosidase (500 mU/mL; Boehringer Mannheim, Castle Hill, Australia), the protein sample (murine serum or muIfnar-2 ECD) was diluted in 0.1% SDS, heated at 95°C for 5 minutes, then incubated for 16 to 24 hours at 37°C in 0.2 M NaOAc, 0.2% Triton X-100 (ICN), and different concentrations of enzyme(s). Where endoglycosidase H (5 U/mL; Boehringer Mannheim) was used, the protein sample was treated as above and incubated in 0.2 M NaOAc. SDS-PAGE and Western blot analysis were then performed as described previously.Binding assays Recombinant muIfnar-2a.
Binding assays for recombinant muIfnar-2a were carried out as
previously described.27,28 ConA Sepharose (Pharmacia) was diluted 1:4 in 100 mM NaOAc pH 6.0, 1 mM MgCl2, 1 mM
MnCl2, 1 mM CaCl2, 0.02% Tween-20, and 0.02%
NaN3. P pastoris-derived recombinant muIfnar-2
ECD at 5 ng/µL and 10 ng/µL was incubated at room temperature for 3 hours with 5 × 105 cpm of 32P-muIFN Serum.
Murine serum was diluted to a final concentration of 1:100 in RPMI 1640 containing 10% FCS, 1% penicillin/streptomycin, 50 mM HEPES pH 7.4, 1 mM CaCl2, and incubated at room temperature for 1 hour with
32P- muIFN Transient transfections Transient expression of muIfnar-2a and muIfnar-2c into COS-7 cells was achieved by electroporation with plasmid DNA essentially as previously described.26 After 72 hours posttransfection, the culture medium was collected, cellular debris removed by centrifugation, and the supernatant concentrated 10-fold by using Centricon-10 columns before Western blot analysis.Stable transfections and luciferase reporter assays For the generation of stable cell lines, the murine fibroblast L929 cell line was transfected with 10 µg of a NotI-digested p2'5'OASLucNeo cDNA by electroporation. Cells were selected with 600 µg/mL Geneticin (Life Technologies) for 2 weeks, resulting in the isolation of 24 resistant clones. To analyze type I IFN responsiveness, 1 × 105 cells from each clone were incubated for 7 hours at 37°C (5% CO2) with 100 IU/mL recombinant muIFN 1, lysed directly in reporter lysis buffer
(Promega), and luciferase light units analyzed on a Lumat
LB9501 Luminometer (Berthold, Melbourne, Australia) by using a
Promega Luciferase Assay kit. The clone (2'5'OASLuc L cells)
showing the greatest IFN-induced luciferase activity was chosen for
subsequent experiments.
Blocking of IFN-induced luciferase activity by recombinant soluble muIfnar-2 An aliquot of 1 × 105 2'5'OASLuc L cells was added to each well of a 24-well plate. After 24 hours, the media was removed and to each well was added in duplicate either 10, 1, or 0 IU/mL muIFN1 or muIFN preincubated at 37°C for 1 hour with
either 100, 10, 1, or 0 ng/mL recombinant muIfnar-2a/muIfnar-2 ECD, or
muIfnar-2a/muIfnar-2 ECD, heat-inactivated at 95°C for 10 minutes.
The plates were incubated at 37°C for 7 hours, then the cells in each
well analyzed for luciferase activity as described previously.
Antiproliferative assays Thymi were removed from C57BL/6XCBA or C57BL/6 age-matched mice, or mice with a null mutation of the muIfnar-2 gene (P.J.H., unpublished data, May 2000), their cells dispersed in PBS through a fine-mesh sieve and washed with PBS. Aliquots of 5 × 105 cells in medium were added to each well of a 96-well flat-bottomed plate, followed by the addition of 40 µg/mL phytohaemagglutinin (PHA; Sigma) and recombinant muIFN with or without purified recombinant muIfnar-2a in quadruplicate as above. After 30 hours incubation at 37°C, 0.0185 MBq (0.5 µCi) 3H-thymidine (ICN) was added to each well. Preliminary experiments showed that 48 hours of PHA stimulation was the optimum time for maximum 3H-thymidine incorporation (a typical experiment gave 2200 cpm compared with a background of about 100 cpm). After a further 18 hours incubation, the thymocytes were harvested by using a Beckman 96-well Micromate cell harvester onto glass fiber disks (Packard, Sydney, Australia). These were placed into separate scintillation vials containing 1 mL scintillant (National Diagnostics, Somerville, NJ) and counted in a 1900TR Liquid Scintillation Analyzer (Packard). The antiproliferative activity of IFN was determined as the percentage reduction in 3H-thymidine incorporation relative to untreated PHA-stimulated thymocytes.Statistical analyses Differences between means were determined using a 2-tailed Student t test.
Expression of muIfnar-2 messenger RNA isoforms in normal adult mouse tissues and during development In order to investigate the in vivo function of muIfnar-2, an extensive panel of poly(A)+ mRNAs from normal adult mouse tissues, primary cells, and murine cell lines was tested for the expression of muIfnar-2 transcripts. Figure 1 shows major transcripts of 1.5 and 4 kb in all the tissues, cells, and cell lines examined. In the majority of tissues tested, the 1.5-kb mRNA transcript encoding muIfnar-2a was more abundant than the 4-kb transcript encoding muIfnar-2c. The levels of each muIfnar-2 transcript relative to the levels of the housekeeping gene GAPDH were quantified using a PhosphorImager (Fuji). Figure 2A shows that there was a range of expression levels in the various tissues of the 1.5-kb transcript encoding muIfnar-2a relative to GAPDH. Similarly, the levels of the 4-kb transcript relative to GAPDH also showed a marked variation between tissues (Figure 2B). The hierarchy of expression for both transcripts in the different mouse tissues was similar in some cases (Figure 2A-B). The most marked exception was the liver in which the ratio of the 1.5-kb transcript relative to GAPDH was high, whereas the relative levels of the 4-kb transcript were comparatively low. Figure 2C shows the ratio of the 1.5-kb transcript (muIfnar-2a) to that of the 4-kb transcript (muIfnar-2c) in a range of tissues. In tissues from the gastrointestinal and urogenital systems, muscle, and connective tissues, high-to-moderate ratios of the 1.5- to 4-kb transcripts were observed. Ratios of more than 10:1 were observed in the small intestine, liver, and fat. However, in the lung and in the tissues of hematopoietic origin, eg, thymus, bone marrow-derived macrophages (BMM), and bone marrow, the ratio of the 1.5- to 4-kb transcript was as low as 0.8:1. These data demonstrate that the expression of the mRNA transcript encoding the soluble receptor muIfnar-2a is greater than that encoding the transmembrane isoform muIfnar-2c in most tissues and that the expression of both isoforms varies markedly between tissues.
Because the expressions of type I IFNs are developmentally
regulated,3 we examined the expression of
muIfnar-2 at different stages of embryonic and neonatal
development. Northern analysis of poly(A)+ mRNA from a
range of tissues during development showed that transcripts encoding
both muIfnar-2a and muIfnar-2c could be detected as early as embryonic
day 10, in all tissues examined from embryonic day 14 (Figure
3A), and in embryonic stem (ES) cells
(Figure 1). Figure 3B shows that the ratio of the intensity of the
1.5-kb transcript (2a) to that of the 4-kb transcript (2c) was low and
virtually unchanged in all the tissues examined during embryonic
development up to the neonate. The 1.5-kb:4-kb transcript ratio was
relatively constant between the neonate and the adult stages in the
lung, spleen, and brain. In contrast, a dramatic increase in the
1.5-kb:4-kb ratio occurred between the neonatal and the adult stages in
the liver and stomach, implying an increased requirement for muIfnar-2a in these tissues.
Characterization of muIfnar-2a protein Because mRNA expression data implied that the regulation of muIfnar-2a was functionally important, it was necessary to characterize the muIfnar-2a protein. To address this question, we produced polyclonal antibodies to recombinant muIfnar-2 ECD produced in P pastoris. In Western blot analysis using the muIfnar-2 polyclonal antibodies, recombinant muIfnar-2a produced in E coli showed a band of approximately 29 kd (Figure 4A, lane 1; 450 ng loaded), whereas purified muIfnar-2 ECD produced in P pastoris showed a band at approximately 42 kd (Figure 4A, lane 2; 30 ng loaded). Western blot analysis of the culture supernatant from COS-7 mammalian cells transfected with a muIfnar-2a expression construct revealed a band at approximately 45 kd (Figure 4A, lane 3). This protein was not present in the culture medium of COS-7 cells transiently transfected with either an expression construct encoding muIfnar-2c or pEF-BOS vector DNA alone (Figure 4A, lanes 4,5). However, a band of the expected size for the transmembrane form of muIfnar-2 was detected in the membrane fraction (data not shown). This latter result indicated that, in this case, the majority of soluble muIfnar-2 protein was not produced by proteolytic cleavage of muIfnar-2c protein at the cell surface, but translated from the muIfnar-2a transcript.
A major band of approximately 45 kd was readily detected in the serum of normal adult mice by Western blot (Figure 4B). This band was not detectable in the serum of mice with a null mutation of the muIfnar-2 gene (P.J.H., unpublished data, May 2000) (Figure 4B). Experiments using recombinant muIfnar-2a as a competitor showed that only the 45-kd band was specifically competed (data not shown). These results confirm the specificity of both the 45-kd band and the anti-muIfnar-2 polyclonal antibodies. In order to obtain an approximate estimate of soluble muIfnar-2 serum concentrations, a comparison of soluble muIfnar-2 protein levels in normal mouse serum to serial dilutions of recombinant muIfnar-2a protein by Western blot analysis indicated that it was present at approximately 20 to 50 µg/mL (data not shown). In order to determine whether the molecular weight difference between E coli-derived recombinant muIfnar-2a and serum muIfnar-2 or muIfnar-2 ECD was due to glycosylation, serum and P pastoris-derived recombinant muIfnar-2 ECD were treated with various N- and O-glycosidases. Treatment of serum with endoglycosidase F resulted in the loss of the specific 45-kd band corresponding to soluble muIfnar-2 and the appearance of multiple bands, ranging in mobility from 44 to 30 kd, which is the observed mobility of E coli-derived muIfnar-2a (Figure 4C). These bands were not due to degradation, as they were not present in untreated serum and serum treated with O-glycosidase. The band at approximately 53 kd is nonspecific because it was unable to be specifically competed with recombinant muIfnar-2. The mobility of P pastoris-derived muIfnar-2 ECD could be reduced to within 3 kd of E coli-derived muIfnar-2a (Figure 4D); the additional 3 kd is due to the myc and His-epitopes present on muIfnar-2 ECD. A range of adult mouse biologic fluids was examined for the presence of soluble muIfnar-2 by Western blot analysis with the polyclonal anti-muIfnar-2 ECD antibody. A 45-kd band corresponding to the muIfnar-2a protein was detected not only in serum, but also at a relatively lower abundance in the urine and a peritoneal wash of normal adult mice (Figure 4E, lanes 1,2,3, respectively). An immunoreactive protein, migrating at approximately 85 to 90 kd, was detected in murine mouth rinsings (Figure 4E, lane 4). The mobility of this protein is suggestive of a dimeric form of muIfnar-2a, although it was unable to be reduced to a lower Mr, even with 1 M DTT as the reducing agent (data not shown). The band corresponding to this protein was able to be competed with recombinant muIfnar-2a (data not shown). The detection of soluble muIfnar-2 in saliva is consistent with the high muIfnar-2a:GAPDH ratio shown in Figure 2A. MuIfnar-2a protein could also be detected at very low levels in the culture media of the L929 and murine 3T3 cell lines (data not shown). Therefore, not only was the muIfnar-2a mRNA transcript expressed at high levels, but there were significant levels of muIfnar-2 protein circulating in vivo, thus providing an opportunity for it to systemically regulate the actions of type I IFNs. Binding of IFN by soluble muIfnar-2 In order to determine whether the soluble receptor could bind IFN ligand, we used the ability of ConA Sepharose to precipitate glycosylated muIfnar-2 ECD bound to the unglycosylated muIFN1. Significant amounts of 32P-muIFN1 (5133 and 6760 cpm)
were precipitated with soluble muIfnar-2 ECD (5 and 10 µg/mL,
respectively). This could be competed with unlabeled muIFN4,
indicating specific binding of the ligand to receptor (Figure
5A). In separate experiments, serum was
mixed with 32P-muIFN1, then applied to Sephadex G-50 gel
filtration columns (Pharmacia) to determine the extent of
high-molecular-weight complex formation. A significant proportion of
32P-muIFN1 was excluded from the column (Figure 5B),
consistent with the presence of receptor-ligand complexes of
Mr greater than or equal to 50 kd (where the Mr
of IFN1 and soluble muIfnar-2 ECD is 20 kd and 42 kd, respectively).
The radioactivity in the high-molecular-weight complex could be
competed with unlabeled muIFN4, indicating that the binding
was specific.
Inhibition of interferon-induced signaling by recombinant muIfnar-2a The ability of muIfnar-2a to perform a biologic function was tested in an in vitro assay system established to measure the ability of muIfnar-2a to act as a competitive inhibitor of type I IFN-induced signaling. Murine L929 cells were stably transfected with a reporter construct containing the promoter of the IFN-inducible gene 2',5'-oligoadenylate synthetase (OAS) linked to the luciferase gene (2'5'OASLuc L cells). Recombinant muIFN1
was able to induce 2',5'-OAS promoter-driven luciferase
activity in these cells in a dose-dependent manner (Figure
6A). The addition of recombinant muIfnar-2a was able to significantly block the IFN1-induced
luciferase activity in a dose-dependent manner, with 70% inhibition of
the activity of 10 IU/mL IFN occurring with as little as 10 ng/mL of
muIfnar-2a (P < .005) (Figure 6A). These levels represent
physiologic concentrations of IFN and approximately equimolar
concentrations of muIfnar-2a protein and muIFN1. A similar
concentration of muIfnar-2a was able to inhibit muIFN-induced
luciferase expression by 50% (P < .005) (Figure 6B). The
amino acid sequence of IFN is the most divergent of the type I IFNs.
A significant basal level of luciferase activity could be measured in
the 2'5'OASLuc L cells when no exogenous IFN1 was added, indicating
some autocrine or paracrine type I IFN production and action in these
cells. All concentrations of muIfnar-2a were also able to block this basal level of IFN and -induced luciferase activity
(P < .025). Recombinant muIfnar-2 ECD had the same
inhibitory effect on IFN-induced luciferase activity in the
2'5'OASLuc L cells as E coli-derived muIfnar-2a
(data not shown), suggesting that this activity was not affected by the
presence of the 11 muIfnar-2a-specific amino acids and that
glycosylation was not necessary for this activity. Viable cell counts
were not significantly altered by the addition of the muIfnar-2a
protein preparation, indicating that the reduction in enzyme activity
was not due to a cytotoxic effect (data not shown). Furthermore, the
addition of a preparation of muIfnar-2a heat inactivated at 95°C for
5 minutes caused no significant reduction in the basal level of
luciferase activity in the 2'5'OASLuc L cells, indicating
that the inhibition was caused specifically by muIfnar-2a protein and
not by another factor in the protein preparation. Therefore, muIfnar-2a
can inhibit the function of type I IFNs by competing with muIfnar-2c
for association in a receptor complex and subsequent signal
transduction.
Inhibition of the antiproliferative effects of type I interferons on thymocytes by muIfnar-2a Primary murine thymocytes were chosen for these experiments because they are sensitive to the antiproliferative and immunoregulatory effects of type I IFNs. Addition of 10 and 100 IU/mL muIFN4 inhibited the proliferation of PHA-stimulated thymocytes by
30% and 50%, respectively. The effect of recombinant muIfnar-2a on
this biologic response was then examined. There was a dose-dependent
inhibition of IFN activity by muIfnar-2a, with the addition of 100 ng/mL of recombinant muIfnar-2a inhibiting the IFN4-induced
antiproliferative action on these cells by about 50%
(P < .01) (Figure 7A).
Heat-inactivated muIfnar-2a had no significant effect on the
PHA-stimulated thymocytes (data not shown), indicating that this effect
was specific to active recombinant muIfnar-2a protein. Recombinant
muIfnar-2a was also able to inhibit the antiviral activity of murine
IFN4 on Semliki Forest virus by 40% and 55% by using 300 and 500 ng/mL, respectively, in a cytopathic reduction effect bioassay (data not shown).
When recombinant muIfnar-2a was added to PHA-stimulated thymocytes in the absence of exogenous type I IFN, a dose-dependent stimulation of proliferation was observed (P < .005 at 10 and 100 ng/mL) (Figure 7B). This result suggested that autocrine or paracrine secretion and action of type I IFN by the primary thymocytes normally exert a basal level of growth inhibition that can be blocked by exogenous muIfnar-2a, resulting in increased proliferation. This is consistent with the reduction of basal reporter activity by recombinant muIfnar-2a (Figure 6A,B). Together, these results importantly demonstrate that muIfnar-2a has an inhibitory effect on the actions of type I IFNs on primary thymocytes. Complementation of the type I interferon response in
muIfnar-2  /
thymocytes, even up to 10 000 IU/mL (data not shown), but after the
addition of 1 to 100 ng/mL recombinant muIfnar-2a plus 100 IU/mL
muIFN4 (Figure 8A) or muIFN (Figure
8B), the antiproliferative response was restored in a dose-dependent
manner. The inhibition by 100 IU/mL muIFN4 or muIFN plus 100 ng/mL muIfnar-2a was up to 60% of the maximum inhibition of
proliferation induced by 100 IU/mL muIFN4 or muIFN on wild-type
thymocytes (P < .005 and .025, respectively). Up to 100 ng/mL heat-inactivated muIfnar-2a did not significantly inhibit
PHA-induced proliferation (data not shown), indicating that the effect
was specific to active recombinant muIfnar-2a. These results suggest
that muIfnar-2a can form a ligand-induced association with the
muIfnar-1 chain of the type I IFN receptor to elicit a partial
antiproliferative response without the requirement of the intracellular
domain of the muIfnar-2c chain. These data also suggest that, in murine thymocytes, type I IFN-induced antiproliferative signals could be
partially transmitted through the cytoplasmic domain of the muIfnar-1
chain of the type I IFN-receptor complex.
The type I IFNs are important in vivo regulators of processes such
as hematopoiesis, immune responses, growth, tumorigenesis, and
responses to infection. In physiologic situations, IFN is not
detectable in serum, but is produced locally and acts in an autocrine
or paracrine manner, whereas in viral infections it can be found at
high levels, up to 1000 IU/mL.30 In addition to the
beneficial effects on the host, type I IFNs can also have adverse
effects as seen after systemic administration of IFN The first step toward demonstrating the biologic significance of a soluble IFN receptor was to determine its in vivo expression relative to the transmembrane receptor. Northern blot analyses showed that there were 2 muIfnar-2 mRNA transcripts of 4.0 and 1.5 kb, the former encoding the transmembrane receptor (muIfnar-2c) and the latter encoding the generally more abundant, soluble isoform (muIfnar-2a). A subsequent study has described a 4.0-kb transcript encoding a second putative soluble receptor isoform (muIfnar-2a').31 However, this transcript is probably of low abundance, as it was only detectable after 60 cycles of PCR. The minor levels of muIfnar-2a' mRNA in the 4.0-kb transcript would, if anything, underestimate the contribution of transcripts for soluble muIfnar-2. In the majority of mouse tissues and cell lines, the ratio of muIfnar-2a:muIfnar-2c (2a:2c) mRNA was about 5:1. However, high ratios (more than 10:1) in tissues such as the liver, small intestine, and fat imply an important function for muIfnar-2a. At the other extreme, there were tissues, particularly those involved in hematopoiesis in which the 2a:2c ratio was low (eg, less than 1:1 in BMM), implying that the production of a soluble receptor by these tissues would be a disadvantage or is unnecessary for the required effect of type I IFNs. As previous studies have shown that the ability to produce and respond to type I IFNs is developmentally regulated,3,32 we examined the expression of muIfnar-2 transcripts during murine embryonic development. Both transcripts were present in all tissues examined throughout development, including ES cells, and the low 2a:2c ratio was maintained through to the neonate. Therefore, if regulated type I IFN responses are important during development, the regulation must occur at the level of IFN ligands or other response genes. Postnatally, some organs maintained the low 2a:2c ratios that existed throughout embryonic development, whereas in others, eg, the liver and small intestine, ratios were increased. The timing of the up-regulation of muIfnar-2a expression implies an environmental stimulus and that soluble muIfnar-2 is required to modulate IFN responses to these stimuli. The range of 2a:2c mRNA ratios in adult tissues and during development demonstrates that the expression levels of both isoforms are regulated, strongly implying a function for muIfnar-2a. Differential expression, splicing, or stability of mRNA transcripts may regulate the mRNA levels. This regulation might produce different stoichiometries of receptor components, resulting in specific responses to the type I IFNs in different organs or cell types. Because the pattern of muIfnar-2a mRNA expression strongly
indicated a function for this isoform, it was important to characterize the muIfnar-2a protein. Western blot analysis of mouse serum, using a
well-characterized polyclonal antiserum, demonstrated that a 45-kd band
representing glycosylated soluble muIfnar-2 was present. The level of
soluble muIfnar-2 in the serum was estimated to be about 20 to 50 µg/mL. This level would be in considerable molar excess compared with
the range of concentrations of serum type I IFN that is seen in an
acute viral infection.30 Experiments demonstrated that the
soluble muIfnar-2 in serum could bind 32P-labeled murine
IFN Recombinant muIfnar-2a or muIfnar-2c ECD was expressed in E coli, P pastoris, or mammalian cells. The product(s) had a mobility of 29-kd nonglycosylated or 45-kd glycosylated, but our data indicated that glycosylation was not important for biologic activities as measured by in vitro assays. Soluble cytokine receptors can be generated by 2 mechanisms, which are not necessarily mutually exclusive: alternative splicing of the same gene as that encoding the transmembrane isoform, or proteolytic cleavage of the cell surface receptor.33 To address the mechanism of soluble receptor generation, a comparison of culture supernatants from cells transfected with muIfnar-2a or muIfnar-2c cDNAs demonstrated that soluble muIfnar-2 was found only in the former. This indicated, at least in this case, that soluble muIfnar-2 was the product of the muIfnar-2a transcript alternatively spliced from the muIfnar-2 gene, which also encodes muIfnar-2c (M.P.H., unpublished data, May 2000), rather than a proteolytically cleaved product of muIfnar-2c. Because in other cytokine systems soluble receptors can act as agonists
or antagonists of the activity of their cognate ligands,33 we investigated whether muIfnar-2a could affect the biologic actions of
type I IFNs. In murine L929 cells, muIfnar-2a inhibited the induction
of an IFN-sensitive reporter in a dose-dependent manner. Interestingly,
muIfnar-2a was an equally potent inhibitor of not only IFN It was then necessary to determine whether muIfnar-2a could modulate a biologic effect of type I IFNs in primary cells. We demonstrated that muIfnar-2a was a potent, dose-dependent inhibitor of the antiproliferative effect of type I IFNs on primary thymocytes, and of the antiviral effect on primary murine embryo fibroblasts. Not only did the soluble muIfnar-2 inhibit exogenous IFN but also the autocrine or paracrine IFN that is produced by these cells and exerts some "basal" effects on cells such as suppression of proliferation. The partial block of this basal activity may have been due to several factors. First, not all of the basal activity may be the consequence of type I IFN activity, but may be due to the actions of other cytokines or endogenous levels of regulatory transcription factors. Secondly, it may be due to the low efficiency of blocking basal activity because of kinetics of interactions with cell-surface receptors; even high-affinity antibodies can be poor blockers of autocrine/paracrine ligand-receptor interactions.34 Therefore, soluble muIfnar-2 could be an important regulator of thymocyte development and responses in vivo. Because some soluble cytokine receptors, such as the soluble IL-6
receptor, can bind the ligand and interact with the other chain of the
receptor complex to transduce a signal,35 we determined whether this was possible for muIfnar-2a using thymocytes from muIfnar-2 These results compel a re-evaluation of how the known components
of the type I IFN receptor might interact with ligands and transduce
their variety of signals. MuIfnar-2a can bind IFN and inhibit the
interaction among ligand, cell surface muIfnar-1, and muIfnar-2c that
is necessary for a full biologic response (Figure
9A-B). Alternatively, the
muIfnar-2a-ligand complex could also interact with cell surface
muIfnar-1 to transduce a partial response (Figure 9D), whereas
muIfnar-1 alone is unable to do so (Figure 9C). This result is
consistent with the demonstration that human IFNAR-2b, a transmembrane
isoform that lacks a complete cytoplasmic domain, can bind ligand and
form a complex with huIFNAR-1, but is inconsistent with the lack of
antiviral signaling or activation of the JAK/STAT
pathway.17,36 One explanation may lie in the different
biologic responses measured. Alternatively, it is possible that the
muIfnar-2a:IFN:muIfnar-1 complex (Figure 9D) may activate a unique
pathway responsible for antiproliferative responses in thymocytes.
Interestingly, it was recently reported that type I IFN elicited an
antiproliferative response in T cells that was independent of the
JAK/STAT pathway and used the ZAP-70/lck/CD45 pathway.37
The agonistic properties of muIfnar-2a have only been demonstrated in
Ifnar-2
The authors thank Dr S. Hwang for providing the muIfnar-2c cDNA cloned into pEF-BOS; L. Gullyan for skilled technical assistance.
Submitted June 28, 1999; accepted August 21, 2000.
Supported by a grant from the National Health and Medical Research Council of Australia. M.P.H. and S.T. are the recipients of Australian Postgraduate Awards.
M.P.H. and C.M.O. contributed equally to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Paul J. Hertzog, Center for Functional Genomics and Human Disease, Monash Institute of Reproduction and Development, 27-31 Wright St, Clayton, Victoria 3168, Australia; e-mail: Paul.Hertzog{at}med.monash.edu.au.
1. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Ann Rev Biochem. 1987;56:727-777[CrossRef][Medline] [Order article via Infotrieve]. 2. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD. How cells respond to interferons. Ann Rev Biochem. 1998;67:227-264[CrossRef][Medline] [Order article via Infotrieve]. 3. Hertzog PJ, Hwang SY, Kola I. Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol Rep Devel. 1994;39:226-232[CrossRef][Medline] [Order article via Infotrieve]. 4. Hamilton JA, Whitty GA, Kola I, Hertzog PJ. Endogenous IFN-alpha beta suppresses colony-stimulating factor (CSF)-1-stimulated macrophage DNA synthesis and mediates inhibitory effects of lipopolysaccharide and TNF-alpha. J Immunol. 1996;156:2553-2557[Abstract].
5.
Luft T, Pang KC, Thomas E, et al.
Type I IFNs enhance the terminal differentiation of dendritic cells.
J Immunol.
1998;161:1947-1953 6. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science. 1996;272:1947-1950[Abstract].
7.
Gutterman JU.
Cytokine therapeutics 8. Weissmann C, Weber H. The interferon genes. Prog Nucleic Acid Res Mol Biol. 1986;33:251-300[Medline] [Order article via Infotrieve]. 9. Uze G, Lutfalla G, Mogensen KE. Alpha and beta interferons and their receptor and their friends and relations. J Interferon Cytokine Res. 1995;15:3-26[Medline] [Order article via Infotrieve]. 10. Uze G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell. 1990;60:225-234[CrossRef][Medline] [Order article via Infotrieve]. 11. Novick D, Cohen B, Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell. 1994;77:391-400[CrossRef][Medline] [Order article via Infotrieve].
12.
Uze G, Lutfalla G, Bandu MT, Proudhon D, Mogensen KE.
Behavior of a cloned murine interferon alpha/beta receptor expressed in homospecific or heterospecific background.
Proc Natl Acad Sci U S A.
1992;89:4774-4778 13. Lutfalla G, Holland SJ, Cinato E, et al. Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J. 1995;14:5100-5108[Medline] [Order article via Infotrieve].
14.
Owczarek CM, Hwang SY, Holland KA, et al.
Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2.
J Biol Chem.
1997;272:23865-23870
15.
Muller U, Steinhoff U, Reis LF, et al.
Functional role of type I and type II interferons in antiviral defense.
Science.
1994;264:1918-1921
16.
Hwang SY, Hertzog PJ, Holland KA, et al.
A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses.
Proc Natl Acad Sci U S A.
1995;92:11284-11288
17.
Domanski P, Witte M, Kellum M, et al.
Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling.
J Biol Chem.
1995;270:21606-21611 18. Cohen B, Novick D, Barak S, Rubinstein M. Ligand-induced association of the type I interferon receptor components. Mol Cell Biol. 1995;15:4208-4214[Abstract].
19.
Gonda TJ, Sheiness DK, Bishop JM.
Transcripts from the cellular homologues of retroviral oncogenes: distribution among chicken tissues.
Mol Cell Biol.
1982;2:617-624
20.
Evan G, Lewis G, Ramsay G, Bishop JM.
Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product.
Mol Cell Biol.
1985;5:3610 21. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989;77:51-59[CrossRef][Medline] [Order article via Infotrieve].
22.
Mizushima S, Nagata S.
pEF-BOS, a powerful mammalian expression vector.
Nucleic Acids Res.
1990;18:5322
23.
Owczarek CM, Zhang Y, Layton MJ, Metcalf D, Roberts B, Nicola NA.
The unusual species cross-reactivity of the leukemia inhibitory factor receptor alpha-chain is determined primarily by the immunoglobulin-like domain.
J Biol Chem.
1997;272:23976-23985 24. Heukeshoven J, Dernick R. Improved silver stain procedure for fast staining in PhastSystem development unit: I, staining of sodium dodocyl sulfate gels. Electrophoresis. 1988;9:28-32[CrossRef][Medline] [Order article via Infotrieve]. 25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254[CrossRef][Medline] [Order article via Infotrieve]. 26. Owczarek CM, Layton MJ, Metcalf D, et al. Inter-species chimeras of leukaemia inhibitory factor define a major human receptor-binding determinant. EMBO J. 1993;12:3487-3495[Medline] [Order article via Infotrieve]. 27. Nicola NA, Cary DA. Affinity conversion of receptors for colony stimulating factors: properties of solubilized receptors. Growth Factors. 1992;6:119-129[Medline] [Order article via Infotrieve].
28.
Layton MJ, Cross BA, Metcalf D, Ward LD, Simpson RJ, Nicola NA.
A major binding protein for leukemia inhibitory factor in normal mouse serum: identification as a soluble form of the cellular receptor.
Proc Natl Acad Sci U S A.
1992;89:8616-8620
29.
Maller JL, Kemp BE, Krebs EG.
In vivo phosphorylation of a synthetic peptide substrate of cyclic AMP-dependent protein kinase.
Proc Natl Acad Sci U S A.
1978;75:248-251 30. Hertzog PJ, Wright A, Harris G, Linnane AW, Mackay IR. Intermittent interferonemia and interferon responses in multiple sclerosis. Clin Immunol Immunopathol. 1991;58:18-32[CrossRef][Medline] [Order article via Infotrieve]. 31. Kim SH, Cohen B, Novick D, Rubinstein M. Mammalian type I interferon receptors consists of two subunits: IFNaR1 and IFNaR2. Gene. 1997;196:279-286[CrossRef][Medline] [Order article via Infotrieve]. 32. Harada H, Willison K, Sakakibara J, Miyamoto M, Fujita T, Taniguchi T. Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. Cell. 1990;63:303-312[CrossRef][Medline] [Order article via Infotrieve]. 33. Rosejohn S, Heinrich PC. Soluble receptors for cytokines and growth factors-generation and biological function. Biochem J. 1994;300:281-290.
34.
Overall ML, Hertzog PJ.
Functional analysis of interferon-alpha subtypes using monoclonal antibodies to interferon-alpha 4a 35. Suzuki H, Yasukawa K, Saito T, et al. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur J Immunol. 1993;23:1078-1082[Medline] [Order article via Infotrieve].
36.
Pfeffer LM, Basu L, Pfeffer SR, et al.
The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action.
J Biol Chem.
1997;272:11002-11005 37. Petricoin EF, Ito S, Williams BL, et al. Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling. Nature. 1997;390:629-632[CrossRef][Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  F. Gilli, P. Valentino, M. Caldano, L. Granieri, M. Capobianco, S. Malucchi, A. Sala, F. Marnetto, and A. Bertolotto Expression and regulation of IFN{alpha}/{beta} receptor in IFN{beta}-treated patients with multiple sclerosis Neurology, December 9, 2008; 71(24): 1940 - 1947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhao, C. Lee, R. Piganis, C. Plumlee, N. de Weerd, P. J. Hertzog, and C. Schindler A Conserved IFN-{alpha} Receptor Tyrosine Motif Directs the Biological Response to Type I IFNs J. Immunol., April 15, 2008; 180(8): 5483 - 5489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. de Weerd, S. A. Samarajiwa, and P. J. Hertzog Type I Interferon Receptors: Biochemistry and Biological Functions J. Biol. Chem., July 13, 2007; 282(28): 20053 - 20057. [Full Text] [PDF]
|
|
|
|
|
|
W. Zhao, E. N. Cha, C. Lee, C. Y. Park, and C. Schindler Stat2-Dependent Regulation of MHC Class II Expression J. Immunol., July 1, 2007; 179(1): 463 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. van Koetsveld, G. Vitale, W. W. de Herder, R. A. Feelders, K. van der Wansem, M. Waaijers, C. H. J. van Eijck, E.-J. M. Speel, E. Croze, A.-J. van der Lely, et al. Potent Inhibitory Effects of Type I Interferons on Human Adrenocortical Carcinoma Cell Growth J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4537 - 4543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vitale, W. W. de Herder, P. M. van Koetsveld, M. Waaijers, W. Schoordijk, E. Croze, A. Colao, S. W.J. Lamberts, and L. J. Hofland IFN-{beta} Is a Highly Potent Inhibitor of Gastroenteropancreatic Neuroendocrine Tumor Cell Growth In vitro Cancer Res., January 1, 2006; 66(1): 554 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Chadha, J. L. Ambrus Jr., W. Dembinski, and J. L. Ambrus Sr. Interferons and Interferon Inhibitory Activity in Disease and Therapy Experimental Biology and Medicine, April 1, 2004; 229(4): 285 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Waubant, S. Vukusic, L. Gignoux, F. D. Dubief, I. Achiti, S. Blanc, C. Renoux, and C. Confavreux Clinical characteristics of responders to interferon therapy for relapsing MS Neurology, July 22, 2003; 61(2): 184 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Dondi, E. Pattyn, G. Lutfalla, X. Van Ostade, G. Uze, S. Pellegrini, and J. Tavernier Down-modulation of Type 1 Interferon Responses by Receptor Cross-competition for a Shared Jak Kinase J. Biol. Chem., December 7, 2001; 276(50): 47004 - 47012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Kotenko, L. S. Izotova, O. V. Mirochnitchenko, E. Esterova, H. Dickensheets, R. P. Donnelly, and S. Pestka Identification, Cloning, and Characterization of a Novel Soluble Receptor That Binds IL-22 and Neutralizes Its Activity J. Immunol., June 15, 2001; 166(12): 7096 - 7103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-S. Han, Y. Chen, T. Ezashi, and R. M. Roberts Antiviral activities of the soluble extracellular domains of type I interferon receptors PNAS, May 3, 2001; (2001) 111139598. [Abstract] [Full Text]
|
|
|
|
|
|
C.-S. Han, Y. Chen, T. Ezashi, and R. M. Roberts Antiviral activities of the soluble extracellular domains of type I interferon receptors PNAS, May 22, 2001; 98(11): 6138 - 6143. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
/
),
1 IU/mL (
), or 0 (
) recombinant muIFN
lessons from interferon alpha.
Proc Natl Acad Sci U S A.
1994;91:1198-1205